Scientific Library of Tomsk State University

   E-catalog        

Image from Google Jackets
Normal view MARC view

Prostate Cancer Prevention electronic resource edited by Jack Cuzick, Mangesh A. Thorat.

Contributor(s): Cuzick, Jack [editor.] | Thorat, Mangesh A [editor.] | SpringerLink (Online service)Material type: TextTextSeries: Recent Results in Cancer ResearchPublication details: Berlin, Heidelberg : Springer Berlin Heidelberg : Imprint: Springer, 2014Description: VIII, 169 p. 11 illus., 4 illus. in color. online resourceContent type: text Media type: computer Carrier type: online resourceISBN: 9783642451959Subject(s): medicine | Oncology | Urology | Medicine & Public Health | Oncology | Urology/Andrology | Cancer ResearchDDC classification: 616.994 LOC classification: RC254-282Online resources: Click here to access online
Contents:
Biology and natural history of prostate cancer -- Nutrition and prostate cancer -- Prostate cancer chemoprevention -- Lifestyle and dietary factors -- GWAS in prostate cancer predisposition and application to screening and prevention -- Risk prediction biomarkers – CCP -- Risk prediction biomarkers - TMPRSS2-ERG -- Risk prediction biomarkers – PCA3 -- Risk adapted chemoprevention for PCa -- Outlook for 5α reductase inhibitors in prostate cancer prevention -- Prostate cancer chemoprevention: Aspirin -- Prostate cancer chemoprevention: DFMO -- Prostate cancer chemoprevention: Lycopene -- Distinguishing aggressive from indolent prostate cancer -- Prognosis and Management of low grade disease - Management of Gleason 6 -- Prostate cancer prevention: Policy & Research implications.
In: Springer eBooksSummary: Prostate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals, and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely.   A wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed, and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5α-reductase inhibitors, DFMO, and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease, and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers.
Tags from this library: No tags from this library for this title. Log in to add tags.
No physical items for this record

Biology and natural history of prostate cancer -- Nutrition and prostate cancer -- Prostate cancer chemoprevention -- Lifestyle and dietary factors -- GWAS in prostate cancer predisposition and application to screening and prevention -- Risk prediction biomarkers – CCP -- Risk prediction biomarkers - TMPRSS2-ERG -- Risk prediction biomarkers – PCA3 -- Risk adapted chemoprevention for PCa -- Outlook for 5α reductase inhibitors in prostate cancer prevention -- Prostate cancer chemoprevention: Aspirin -- Prostate cancer chemoprevention: DFMO -- Prostate cancer chemoprevention: Lycopene -- Distinguishing aggressive from indolent prostate cancer -- Prognosis and Management of low grade disease - Management of Gleason 6 -- Prostate cancer prevention: Policy & Research implications.

Prostate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals, and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely.   A wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed, and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5α-reductase inhibitors, DFMO, and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease, and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers.

There are no comments on this title.

to post a comment.